ERBB3 and neoplasm: demonstrated that adipocyte precursor-derived neuregulin 1 (NRG1) promotes resistance to FGFR inhibition by activating the epidermal growth factor receptor 3 (ERBB3; also known as HER3) signaling pathway, which can bypass the inhibited FGFR3 pathway to sustain tumor cell proliferation (73).